Development of novel antagonists of the cell surface adrenomedullin 2 receptor for the treatment of pancreatic cancer (360G-Wellcome-104046_Z_14_C)

£100,000

Pancreatic cancer is the 10th most common cancer, but in the next 15 years, it will become the second highest cause of cancer-related death. Unlike almost all other cancers, the prognosis has not changed in the last 30 years. After diagnosis, outcomes are very poor, with 1-year and 5-year survival rates of <25% and <5% respectively. The best current therapies offer only a few months of increased life expectancy, and patients’ quality of life is poor despite palliative treatments. There is clearly a pressing need for better treatments for pancreatic cancer. A team from the University of Sheffield led by Professor Tim Skerry, with Peakdale Molecular and Sandexis Medicinal Chemistry have been awarded Seeding Drug Discovery funding to develop selective antagonists of the adrenomedullin-2 receptor. Adrenomedullin is a hormone involved in cancer growth and spread, which also has important roles in the control of blood pressure. Adrenomedullin acts through two different receptors one of which mostly regulates blood pressure. The other has important roles in cancer biology. The team have shown that in model systems, blockade of the receptor reduces tumour growth and spread. They will develop their existing novel lead compounds to block the adrenomedullin-2 receptor and inhibit its important roles in cancer, while keeping its normal functions.

Where is this data from?

This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.

Grant Details

Amount Awarded 100000
Applicant Surname Skerry
Approval Committee Seeding Drug Discovery Committee
Award Date 2017-10-01T00:00:00+00:00
Financial Year 2017/18
Grant Programme: Title Seeding Drug Discovery Award
Internal ID 104046/Z/14/C
Lead Applicant Prof Timothy Skerry
Partnership Value 100000
Planned Dates: End Date 2017-12-19T00:00:00+00:00
Planned Dates: Start Date 2017-11-22T00:00:00+00:00
Recipient Org: Country United Kingdom
Region Yorkshire and the Humber